Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Lexeo Therapeutics (NASDAQ: LXEO) announced it will present new data on its AAV manufacturing optimization at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) from May 13-17, 2025, in New Orleans. The company will showcase two presentations highlighting their Sf9-baculovirus manufacturing platform, which demonstrates improved scalability, reduced costs, and maintained purity and potency in AAV production.
The presentations include research on improving VP1 ratios' impact on CQAs in rh10 AAV manufacturing and the development of a novel high-yielding scalable platform capable of producing quality AAV at 200L scale. According to Chief Technical Officer José Manuel Otero, these advancements will help accelerate the company's clinical-stage gene therapy programs and mission to deliver transformative therapies to patients.
Lexeo Therapeutics (NASDAQ: LXEO) ha annunciato che presenterà nuovi dati sull'ottimizzazione della produzione di AAV al 28° Incontro Annuale della American Society of Gene & Cell Therapy (ASGCT), che si terrà dal 13 al 17 maggio 2025 a New Orleans. L'azienda proporrà due presentazioni che mettono in luce la loro piattaforma di produzione Sf9-baculovirus, che dimostra una migliore scalabilità, costi ridotti e il mantenimento di purezza e potenza nella produzione di AAV.
Le presentazioni includono ricerche sull'impatto del miglioramento del rapporto VP1 sulle caratteristiche qualitative critiche (CQA) nella produzione di AAV rh10 e lo sviluppo di una nuova piattaforma scalabile ad alto rendimento in grado di produrre AAV di qualità a scala da 200L. Secondo il Chief Technical Officer José Manuel Otero, questi progressi contribuiranno ad accelerare i programmi di terapia genica in fase clinica dell'azienda e la missione di offrire terapie trasformative ai pazienti.
Lexeo Therapeutics (NASDAQ: LXEO) anunció que presentará nuevos datos sobre la optimización de la fabricación de AAV en la 28ª Reunión Anual de la Sociedad Americana de Terapia Génica y Celular (ASGCT), que se celebrará del 13 al 17 de mayo de 2025 en Nueva Orleans. La compañía mostrará dos presentaciones que destacan su plataforma de fabricación Sf9-baculovirus, la cual demuestra una mejor escalabilidad, reducción de costos y mantenimiento de la pureza y potencia en la producción de AAV.
Las presentaciones incluyen investigaciones sobre la mejora de las proporciones de VP1 y su impacto en los atributos críticos de calidad (CQA) en la fabricación de AAV rh10, así como el desarrollo de una nueva plataforma escalable de alto rendimiento capaz de producir AAV de calidad a escala de 200L. Según el Director Técnico José Manuel Otero, estos avances ayudarán a acelerar los programas de terapia génica en fase clínica de la compañía y su misión de ofrecer terapias transformadoras a los pacientes.
Lexeo Therapeutics (NASDAQ: LXEO)는 2025년 5월 13일부터 17일까지 뉴올리언스에서 개최되는 제28회 미국 유전자 및 세포 치료학회 연례회의(ASGCT)에서 AAV 제조 최적화에 관한 새로운 데이터를 발표할 예정입니다. 회사는 향상된 확장성, 비용 절감, 그리고 AAV 생산에서 순도와 효능 유지를 보여주는 Sf9-바큘로바이러스 제조 플랫폼을 강조하는 두 건의 발표를 진행합니다.
발표 내용에는 rh10 AAV 제조 시 VP1 비율 개선이 핵심 품질 속성(CQA)에 미치는 영향에 관한 연구와 200L 규모에서 고품질 AAV를 생산할 수 있는 고수율 확장형 신규 플랫폼 개발이 포함됩니다. 최고기술책임자(CTO)인 José Manuel Otero에 따르면, 이러한 진보는 회사의 임상 단계 유전자 치료 프로그램과 혁신적인 치료법을 환자에게 제공하려는 사명을 가속화하는 데 기여할 것입니다.
Lexeo Therapeutics (NASDAQ : LXEO) a annoncé qu'elle présentera de nouvelles données sur l'optimisation de la fabrication des AAV lors du 28e congrès annuel de l'American Society of Gene & Cell Therapy (ASGCT) qui se tiendra du 13 au 17 mai 2025 à La Nouvelle-Orléans. La société mettra en avant deux présentations illustrant leur plateforme de fabrication Sf9-baculovirus, qui offre une meilleure évolutivité, des coûts réduits ainsi qu'une pureté et une puissance maintenues dans la production des AAV.
Les présentations porteront sur la recherche visant à améliorer le ratio VP1 et son impact sur les attributs critiques de qualité (CQA) dans la fabrication des AAV rh10, ainsi que sur le développement d'une nouvelle plateforme évolutive à haut rendement capable de produire des AAV de qualité à l'échelle de 200 litres. Selon le directeur technique José Manuel Otero, ces avancées contribueront à accélérer les programmes de thérapie génique en phase clinique de la société et sa mission de fournir des thérapies transformantes aux patients.
Lexeo Therapeutics (NASDAQ: LXEO) gab bekannt, dass es neue Daten zur Optimierung der AAV-Herstellung auf dem 28. Jahreskongress der American Society of Gene & Cell Therapy (ASGCT) vom 13. bis 17. Mai 2025 in New Orleans präsentieren wird. Das Unternehmen wird zwei Präsentationen vorstellen, die ihre Sf9-Baculovirus-Herstellungsplattform hervorheben, welche eine verbesserte Skalierbarkeit, reduzierte Kosten sowie die Aufrechterhaltung von Reinheit und Wirksamkeit bei der AAV-Produktion demonstriert.
Die Präsentationen umfassen Forschungen zur Verbesserung der VP1-Verhältnisse und deren Einfluss auf kritische Qualitätsattribute (CQA) bei der Herstellung von rh10 AAV sowie die Entwicklung einer neuartigen, hochskalierbaren Plattform, die in der Lage ist, qualitativ hochwertige AAV im 200-Liter-Maßstab zu produzieren. Laut Chief Technical Officer José Manuel Otero werden diese Fortschritte dazu beitragen, die klinischen Gentherapieprogramme des Unternehmens zu beschleunigen und die Mission zu unterstützen, transformative Therapien für Patienten bereitzustellen.
- None.
- None.
Research highlights AAV manufacturing optimization via Lexeo’s Sf9-baculovirus process
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, LA.
“The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality,” said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics. “Scientists at Lexeo have optimized a manufacturing platform that can maintain purity and potency while significantly improving scalability of production and reducing cost. Ultimately this platform will enable Lexeo to deliver more efficiently against key milestones in our clinical-stage gene therapy programs and will help to accelerate our mission to bring potentially transformative therapies to patients as quickly as possible.”
Presentation Details:
Title: Improving VP1 Ratios Impact on CQAs in rh10 AAV Manufactured through Sf9 Platform
Presenter: Elena Bianchetti, Lexeo Therapeutics
Date/Time: Tuesday, May 13, 6:00 – 7:30 p.m. CST
Session Title: Tuesday Poster Reception
Abstract Number: 948
Title: Development of a Novel High-Yielding Scalable Sf9-Baculovirus Platform to Produce Quality AAV at 200L Scale
Presenter: Eric Lin, Lexeo Therapeutics
Date/Time: Thursday, May 15, 5:30 – 7:00 p.m. CST
Session Title: Thursday Poster Reception
Abstract Number: 1972
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, LX2020 for the treatment of plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, and the timing and likelihood of potential regulatory approval. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Annual Report on Form 10-K for the annual period ended December 31, 2024, filed with the SEC on March 24, 2025 and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
Media Response:
Media@lexeotx.com
FAQ
What will Lexeo Therapeutics (LXEO) present at the 2025 ASGCT Annual Meeting?
What are the key benefits of Lexeo Therapeutics' new AAV manufacturing platform?
When and where will Lexeo Therapeutics (LXEO) present at ASGCT 2025?
Who is presenting the AAV manufacturing research for Lexeo at ASGCT 2025?
